THOX.F Stock Overview
An in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BioPorto A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 0.29 |
| 52 Week High | DKK 0.43 |
| 52 Week Low | DKK 0.23 |
| Beta | 1.19 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 23.56% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -33.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| THOX.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -10.5% | -2.1% |
| 1Y | 23.6% | 12.7% | 29.7% |
Return vs Industry: THOX.F matched the US Biotechs industry which returned 23.2% over the past year.
Return vs Market: THOX.F underperformed the US Market which returned 30.2% over the past year.
Price Volatility
| THOX.F volatility | |
|---|---|
| THOX.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: THOX.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine THOX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 27 | Peter Eriksen | bioporto.com |
BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was incorporated in 1917 and is based in Hellerup, Denmark.
BioPorto A/S Fundamentals Summary
| THOX.F fundamental statistics | |
|---|---|
| Market cap | US$123.97m |
| Earnings (TTM) | -US$7.48m |
| Revenue (TTM) | US$5.06m |
24.5x
P/S Ratio-16.6x
P/E RatioIs THOX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THOX.F income statement (TTM) | |
|---|---|
| Revenue | DKK 33.83m |
| Cost of Revenue | DKK 9.55m |
| Gross Profit | DKK 24.28m |
| Other Expenses | DKK 74.29m |
| Earnings | -DKK 50.01m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 30, 2024
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 71.76% |
| Net Profit Margin | -147.84% |
| Debt/Equity Ratio | 0% |
How did THOX.F perform over the long term?
See historical performance and comparison